Table 1.
Baseline demographics and disease characteristics
| 1100 mg AMG 820 + 200 mg pembrolizumab (n=98) | 1400 mg AMG 820 + 200 mg pembrolizumab (n=18) |
All patients (N=116) |
|
| Sex, n (%) | |||
| Male | 65 (66.3) | 9 (50.0) | 74 (63.8) |
| Female | 33 (33.7) | 9 (50.0) | 42 (36.2) |
| Ethnicity, n (%) | |||
| Hispanic/Latino | 4 (4.1) | 1 (5.6) | 5 (4.3) |
| Not Hispanic/Latino | 90 (91.8) | 17 (94.4) | 107 (92.2) |
| Unknown | 4 (4.1) | 0 (0.0) | 4 (3.4) |
| Race, n (%) | |||
| White | 88 (89.8) | 15 (83.3) | 103 (88.8) |
| Asian | 3 (3.1) | 2 (11.1) | 5 (4.3) |
| Black (or African–American) | 4 (4.1) | 0 (0.0) | 4 (3.4) |
| Other | 3 (3.1) | 1 (5.6) | 4 (3.4) |
| Age, median (range), years | 64 (37–86) | 58 (30–72) | 64 (30–86) |
| ECOG performance status, n (%) | |||
| 0 | 38 (38.8) | 5 (27.8) | 43 (37.1) |
| 1 | 60 (61.2) | 13 (72.2) | 73 (62.9) |
| Number of prior lines of therapy, n (%) | |||
| 1 | 7 (7.1) | 2 (11.1) | 9 (7.8) |
| 2 | 30 (30.6) | 5 (27.8) | 35 (30.2) |
| 3 | 29 (29.6) | 7 (38.9) | 36 (31.0) |
| 4 | 16 (16.3) | 2 (11.1) | 18 (15.5) |
| 5 | 16 (16.3) | 2 (11.1) | 18 (15.5) |
Includes data for all enrolled patients.
ECOG, Eastern Cooperative Oncology Group.